FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:1710-1714 December 10, 1992 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression. We postulated that the tissue expression of the small RNA transcribed by the EBER-1 gene during latent EBV infection would identify patients at risk for PTLD. METHODS. We studied EBER-1 gene expression in liver specimens obtained from 24 patients 2 days to 22 months before the development of PTLD, using in situ hybridization with an oligonucleotide probe. Control specimens were obtained from 20 recipients of allografts with signs of injury due to organ retrieval, acute graft rejection, or viral hepatitis in whom PTLD had not developed 9 to 71 months after the biopsy. RESULTS. Of the 24 patients with PTLD, 17 (71 percent) had specimens in which 1 to 40 percent of mononuclear cells were positive for the EBER-1 gene. In addition, 10 of these 17 patients (59 percent) had specimens with histopathological changes suggestive of EBV hepatitis. In every case, EBER-1-positive cells were found within the lymphoproliferative lesions identified at autopsy. Only 2 of the 20 controls (10 percent) had specimens with EBER-1-positive cells (P < 0.001), and such cells were rare. CONCLUSIONS. EBER-1 gene expression in liver tissue precedes the occurrence of clinical and histologic PTLD. The possibility of identifying patients at risk by the method we describe here and preventing the occurrence of PTLD by a timely reduction of immunosuppression needs to be addressed by future prospective studies.

Source Information

Division of Transplantation Pathology, University of Pittsburgh, PA.

This article has been cited by other articles:

• Arias, L. F., Hernandez, S., Prats, D., Sanchez-Fructoso, A., Marques, M., Alvarez, T., Barrientos, A., Blanco, J. (2003). Epstein-Barr virus latency in kidney specimens from transplant recipients. Nephrol Dial Transplant 18: 2638-2643 [Abstract] [Full Text]  
• Andreone, P., Gramenzi, A., Lorenzini, S., Biselli, M., Cursaro, C., Pileri, S., Bernardi, M. (2003). Posttransplantation Lymphoproliferative Disorders. Arch Intern Med 163: 1997-2004 [Abstract] [Full Text]  
• Meru, N, Davison, S, Whitehead, L, Jung, A, Mutimer, D, Rooney, N, Kelly, D, Niedobitek, G (2001). Epstein-Barr virus infection in paediatric liver transplant recipients: detection of the virus in post-transplant tonsillectomy specimens. Mol. Pathol. 54: 264-269 [Abstract] [Full Text]  
• Swinnen, L. J. (2000). Post-transplant Lymphoproliferative Disorders: Implications for Acquired Immunodeficiency Syndrome-Associated Malignancies. J Natl Cancer Inst Monogr 2000: 38-43 [Abstract] [Full Text]  
• KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D. JR., SINGER, G. G. (2000). Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. J. Am. Soc. Nephrol. 11: S1-S86 [Abstract] [Full Text]  
• Cohen, J. I. (2000). Epstein-Barr Virus Infection. NEJM 343: 481-492 [Full Text]  
• Limaye, A. P., Huang, M.-L., Atienza, E. E., Ferrenberg, J. M., Corey, L. (1999). Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders. J. Clin. Microbiol. 37: 1113-1116 [Abstract] [Full Text]  
• Kimura, H., Morita, M., Yabuta, Y., Kuzushima, K., Kato, K., Kojima, S., Matsuyama, T., Morishima, T. (1999). Quantitative Analysis of Epstein-Barr Virus Load by Using a Real-Time PCR Assay. J. Clin. Microbiol. 37: 132-136 [Abstract] [Full Text]  
• Benkerrou, M., Jais, J.-P., Leblond, V., Durandy, A., Sutton, L., Bordigoni, P., Garnier, J. L., Le Bidois, J., Le Deist, F., Blanche, S., Fischer, A. (1998). Anti-B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term Outcome. Blood 92: 3137-3147 [Abstract] [Full Text]  
• Deeg, H. J., Socie, G. (1998). Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers. Blood 91: 1833-1844 [Full Text]  
• Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K., Raab-Traub, N. (1995). Clonal Proliferations of Cells Infected with Epstein-Barr Virus in Preinvasive Lesions Related to Nasopharyngeal Carcinoma. NEJM 333: 693-698 [Abstract] [Full Text]  
• Francis, J. B., Ilyas, M., Trendell-Smith, N., Snead, D., Randhawa, P., Pagano, J. S. (1993). Expression of Epstein-Barr Virus in Liver-Transplant Recipients with Lymphoproliferative Disease. NEJM 329: 208-209 [Full Text]